<DOC>
	<DOCNO>NCT00851461</DOCNO>
	<brief_summary>This therapeutic trial study demonstrate whether Goserelin , LHRH agonist benefit SBMA Objective : 1 . To study effect Goserelin clinical course patient spinal bulbar muscular atrophy Thailand 2 . To demonstrate physiological pathological change treat patient Goserelin . 3 . To assess tolerability adverse effect Goserelin therapy</brief_summary>
	<brief_title>Effect Goserelin ( ZoladexÂ® ) Spinal Bulbar Muscular Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Muscular Disorders , Atrophic</mesh_term>
	<mesh_term>Bulbo-Spinal Atrophy , X-Linked</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>1 . Provision inform consent 2 . Males , age 20 year , undesired fertility 3 . Have positive family history muscle weakness clinical sign : bulbar involvement ( difficulty breathing , swallow , talk ) muscle atrophy without fasciculation decrease normal deep tendon reflex normal Babinski response sensory impairment mild tremor ( either postural intention ) gynecomastia decrease libido infertility 4 . Subjects confirm diagnosis SBMA NCV test DNA study demonstrate number CAG repeat 35 . 1 . Have weakness cause etiology liver kidney disease . 2 . Have currently prostatic cancer 3 . Want child 4 . Participation clinical study last 30 day . 5 . Females child age &lt; 20 year old</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Spinobulbar muscular atrophy</keyword>
	<keyword>Kennedy 's disease</keyword>
	<keyword>Goserelin</keyword>
	<keyword>Electrophysiologic study</keyword>
	<keyword>Inclusion body</keyword>
</DOC>